Ralmitaront

CAS No. 2133417-13-5

Ralmitaront ( RO6889450 )

Catalog No. M23969 CAS No. 2133417-13-5

Ralmitaront is a potent, orally active partial agonist of the trace amine-associated receptor 1 (TAAR1).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 267 In Stock
10MG 434 In Stock
25MG 669 In Stock
50MG 896 In Stock
100MG 1269 In Stock
200MG 1701 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Ralmitaront
  • Note
    Research use only, not for human use.
  • Brief Description
    Ralmitaront is a potent, orally active partial agonist of the trace amine-associated receptor 1 (TAAR1).
  • Description
    Ralmitaront is a potent, orally active partial agonist of the trace amine-associated receptor 1 (TAAR1).
  • Synonyms
    RO6889450
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    amine-associated receptor 1 (TAAR1)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2133417-13-5
  • Formula Weight
    314.4
  • Molecular Formula
    C17H22N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:90mg/ml(286.28mM; Need ultrasonic)
  • SMILES
    CCc1c(C)c(C(Nc2ccc([C@@H]3OCCNC3)cc2)=O)n[nH]1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Brady LS, Potter WZ, Gordon JA. Redirecting the revolution: new developments in drug development for psychiatry. Expert Opin Drug Discovery. 2019;14:1213–1219.
molnova catalog
related products
  • Fomesafen

    Fomesafen is a diphenyl ether herbicide and an inhibitor of efficient and selective protoporphyrinogen IX oxidase (PPO).

  • GLP-1 moiety from Du...

    GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-like peptide 1 receptor (GLP-1) agonist.

  • CEP dipeptide 1

    CEP dipeptide 1 is a CEP dipeptide with potent angiogenic activity; mediators of age-related macular degeneration (AMD).